ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma - Episode 6

Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

November 30, 2023

Michael Postow, MD, John M. Kirkwood, MD, Meredith McKean, MD, MPH, Helen Moon, MD, Sapna Patel, BA, MD

Experts discuss a preference for ipilimumab/nivolumab as the frontline immunotherapy for patients with BRAF-mutant metastatic melanoma given its proven long-term efficacy but acknowledge nivolumab/relatlimab as an option with less toxicity, especially adrenal insufficiency.

EP. 1: The Role of Biomarker Testing in the Management of Metastatic Melanoma

EP. 2: Best Practices for Biomarker Testing in Metastatic Melanoma

EP. 3: Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma

EP. 4: Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation

EP. 5: Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma

Now Viewing

EP. 6: Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

EP. 7: Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma

EP. 8: Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma

EP. 9: Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

EP. 10: Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

EP. 11: Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases